Anti-MADD Antibody

Anti-MADD Antibody

• Description: Rabbit Polyclonal Antibody specific to MADD (CT)
• Product Name Alternative: Differentially expressed in normal and neoplastic cells, Insulinoma glucagonoma clone 20, Rab3 GDP/GTP exchange factor, RabGEF, Rab3 GDP/GTP exchange protein, Rab3GEP
• CAS Number: 9007-83-4
• Gene Name: MADD
• Gene ID: 8567
• NCBI Gene ID: MADD
• UniProt: Q8WXG6
• Accession Number: NP_001129415
• Cellular Locus: Cell membrane, Cytoplasm, Cell projection, axon
• Host: Rabbit
• Reactivity: Human, Mouse
• Immunogen: Peptide corresponding to aa 1570-1588 of human MADD. This peptide sequence is identical to that of DENN and differs by one amino acid with rat GDP/GTP exchange protein RAB3-GEP.
• Target Antigen: MAP kinase-activating death domain protein
• Target: MADD
• Clonality: Polyclonal
• Isotype: IgG
• Type: Antibody
• Applications: ELISA, WB, ICC, IF
• Field of Research: Apoptosis
• Purification Method: Purified by peptide immuno-affinity chromatography
• Concentration: Lot Specific
• Dilution: Dilute in PBS or medium which is identical to that used in the assay system.
• Format: Purified
• Form: Liquid
• Buffer: Phosphate Buffered Saline
• Function: Guanyl-nucleotide exchange factor that regulates small GTPases of the Rab family (PubMed:20937701, PubMed:18559336). Converts GDP-bound inactive form of RAB27A and RAB27B to the GTP-bound active forms (PubMed:20937701, PubMed:18559336). Converts GDP-bound inactive form of RAB3A, RAB3C and RAB3D to the GTP-bound active forms, GTPases involved in synaptic vesicle exocytosis and vesicle secretion (By similarity). Plays a role in synaptic vesicle formation and in vesicle trafficking at the neuromuscular junction (By similarity). Involved in up-regulating a post-docking step of synaptic exocytosis in central synapses (By similarity). Probably by binding to the motor proteins KIF1B and KIF1A, mediates motor-dependent transport of GTP-RAB3A-positive vesicles to the presynaptic nerve terminals (By similarity). Plays a role in TNFA-mediated activation of the MAPK pathway, including ERK1/2 (PubMed:32761064). May link TNFRSF1A with MAP kinase activation (PubMed:9115275). May be involved in the regulation of TNFA-induced apoptosis (PubMed:11577081, PubMed:32761064). {UniProtKB:O08873, UniProtKB:Q80U28, PubMed:11577081, PubMed:18559336, PubMed:20937701, PubMed:32761064, PubMed:9115275}.
• Additionnal Information: Immunoblotting : use at 1:250-1:500 dilution.
  
  Positive control: Whole cell lysate from HeLa or NIH3T3 cells.
• Storage Conditions: This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.
• Specificity: This antibody recognizes human and mouse MADD (200-220 kD).
• Formulation: PBS, pH 7.4.
• Buffer pH: pH 7.4
• Target Background: MAP kinase-activating death domain protein (MADD) was initially identified as the type 1 tumor necrosis factor receptor (TNFR1). Overexpression of MADD activates MAP kinases ERK and JNK and induces the phosphorylation of cytosolic phospholipase A2. MADD shares 98% homology with DENN (differentially expressed in neoplasic vs. normal cells) which was recently identified as a substrate for c-jun N-terminal kinase 3 (JNK3). MADD has greather than 94% homology with a GDO/GTP exchange protein , Rab3-GEP, and it is 87% homologous with KIAA0358, a brain protein of unknown function. Identification of MADD as a component of the TNFR1 signalling complex and the similarity between MADD and Rab3-GEP provides a connection between TNFR1 activation and downstream MAP kinase activity through a guanine-nucleotide exchange protein.